Approval of Ribasphere 200mg for treatment of chronic hepatitis C
CRANBERRY TOWNSHIP, PA., April 07, 2004 -- Three Rivers
Pharmaceuticals announced that the FDA has granted marketing
approval for its Ribasphere (ribavirin capsules) 200mg in
combination with interferon alfa-2b for the treatment of Hepatitis
President and CEO Donald J. Kerrish, RPh. stated: "The approval of Ribasphere marks a milestone in the treatment of HCV. Ribasphere is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease." Traditionally the cost of treatment for HCV can range from $20,000 - $25,000 annually. "Our aim is to bring affordable medicine to all individuals infected with this dreadful disease."
Hepatitis C affects nearly 4 million Americans and 170 million people worldwide. HCV is responsible for 8,000 to 10,000 deaths per year in the United States and is the number one cause of liver transplants. HCV can also lead to cirrhosis, end-stage liver disease, and liver cancer. Over 30,000 new cases are diagnosed each year.
Source: Three Rivers Pharmaceuticals www.3riverspharma.com
Posted: April 2004